Safety profile of protein kinase inhibitors in rheumatoid arthritis: Systematic review and meta-analysis

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 871-882

  Salgado, Eva ^a   Maneiro, Jose R ^a   Carmona, Loreto ^a,b   Gomez Reino, Juan J ^a,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ADELATINIB; BARICITINIB; BMS 582949; DILMAPIMOD; DORAMAPIMOD; FOSTAMATINIB; GLPG 0634; IMATINIB; JANUS KINASE; MASITINIB; PAMAPIMOD; PLACEBO; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK; STEM CELL FACTOR RECEPTOR; SYNAPTOPHYSIN; TALMAPIMOD; TOFACITINIB; UNCLASSIFIED DRUG; VX 702;

ANEMIA; ARTICLE; COMORBIDITY; DEATH; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; HEADACHE; HEMATURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MORBIDITY; NAUSEA; NEUTROPENIA; NEUTROPHILIA; OPPORTUNISTIC INFECTION; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL (TOPIC); PILOT STUDY; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

AUTOIMMUNE DISEASES; RHEUMATOID ARTHRITIS; TREATMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PROTEIN KINASE INHIBITORS;

EID: 84898012375     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-203116     Document Type: Article

References (81)

1. Manning G, Whyte D, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34 (Pubitemid 35425239)
2. Sugiura R, Satoh R, Ishiwata S, et al. Role of RNA-binding proteins in MAPK signal transduction pathway. Signal Transduct. Published Online Ahead of print: 5 April 2011. doi:10.1155/2011/109746
3. Endicott J, Noble M, Johnson L. The structural basis for control of eukaryotic protein kinases. Annu Rev Biochem 2012;81:587-613
4. Page T, Brown A, Timms E, et al. Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: Does variable inhibition of interleukin-6 production limit effectiveness in vivo? Arthritis Rheum 2010;62:3221-31
5. Goldstein D, Kuglstatter A, Lou Y, et al. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 2010;53:2345-53
6. Tanaka Y, Maeshima Y, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl 2):i70-4
7. Kyttaris VC. Kinase inhibitors: A new class of antirheumatic drugs. Drug Des Devel Ther 2012;6:245-50
8. Norman P. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Expert Opin Ther Pat 2012;22:1233-49
9. Keystone E, Taylor P, Genovese M, et al. 12-week results of a phase 2b dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional DMARDs in patients with Rheumatoid Arthritis. Ann Rheum Dis 2012;71(Suppl3):152
10. Rousset D, Agnes F, Lachaume P, et al. Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains. J Mol Evol 1995;41:421-9
11. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link? Immunol Today 1994;15:111-14
12. Yarden Y, Kuang W, Yang-Feng T, et al. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-51
13. Besmer P, Murphy JE, George PC, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320:415-21 (Pubitemid 16097805)
14. Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 1994;91:459-63 (Pubitemid 24041421)
15. Juurikivi A, Sandler C, Lindstedt K, et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: A potential approach to the treatment of arthritis. Ann Rheum Dis 2005;64:1126-31 (Pubitemid 41113344)
16. Ashman L, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs. 2013;22:103-15
17. Paniagua R, Sharpe O, Ho P, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006;116:2633-42 (Pubitemid 44511627)
18. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009;4:e7258
19. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol 2010;10:387-402
20. Madhusudan, Trafny, Xuong EN, et al. cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer. Protein Sci 1994;3:176-87
21. Xie L, Evangelidis T, Bourne PE. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol 2011;7:e1002037
22. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-44 (Pubitemid 46652481)
23. Lindstrom T, Robinson W. A multitude of kinases-which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin North Am 2010;36:367-83
24. Genovese M. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20
25. Hammaker D, Firestein GS. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis 2010;69(Suppl 1):i77-82
26. Montalban A, Boman E, Chang C, et al. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. Eur J Pharmacol 2010;632:93-102
27. Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339: b2700
28. Pfizer Briefing Document of Advisory Committee Meeting. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ ArthritisAdvisoryCommittee/UCM302960.pdf (accessed 1 Sep 2012)
29. Higgins J, Altman D, Gotzsche P, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928
30. OCEBM Levels of Evidence Working Group. http://www.cebm.net/index.aspx? o=5653 (accessed 1 Oct 2012)
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88 (Pubitemid 17189972)
32. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34 (Pubitemid 27387172)
33. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58 (Pubitemid 34746062)
34. Higgins J, Thompson S, Deeks J, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60 (Pubitemid 37088507)
35. Kavanaugh A, Weinblatt M, Genovese M, et al. Longer-term safety of fostamatinib (R788) in patients with rheumatoid arthritis. Analysis of clinical trial data from up to 2 years of exposure. Arthritis Rheum 2011;63(Supp 10):32
36. Anand P, Shenoy R, Palmer J, et al. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain 2011;15:1040-8
37. Kremer J, Cohen S, Wilkinson B, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970-81
38. Fleischmann R, Cutolo M, Genovese M, et al. Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Arthritis Rheum 2011;64:617-29
39. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150-8
40. van Vollenhoven R, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19
41. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507
42. Cohen S, Cheng T, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60: 335-44
43. Ananieva O, Darragh J, Johansen C, et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 2008;9:1028-36
44. Kremer J, Bloom B, Breedveld F, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905
45. Fleischmann R, Spencer-Green G, Fan F, et al. Dose Ranging Study of VX-509, An Oral Selective JAK3 Inhibitor, As Monotherapy in Patients with Active Rheumatoid Arthritis (RA). Late Breaking Abstracts. ACR/ARHP Scientific Meeting. 2011. https:// acr.confex.com/acr/2011/webprogram/Paper24549.html (accessed 1 Sep 2012)
46. Genovese M, McKay J, Nasonov E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80
47. van 't Klooster G, Van Rompaey L, Menet C, et al. Preclinical and early clinical evaluation of GLPG0634, a combined jak/tyk2 inhibitor for the treatment of Rheumatoid Arthritis. Ann Rheum Dis 2011;70(Suppl 3):603
48. Vanhoutte F, Mazour M, Namour F, et al. Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of Rheumatoid Arthritis; results of a phase IIa trial. Ann Rheum Dis 2012;71(Suppl 3):145
49. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004;15:2115-24 (Pubitemid 39031350)
50. Semela D, Das A, Langer D, et al. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology 2008;135:671-9
51. Sanders K. A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology 1996;111:492-515 (Pubitemid 26256739)
52. Genovese M, Ling G, Yin J, et al. Proof of concept study for a potent p38 MAPK dual action inhibitor BMS-582949 in subjects with RA aeceiving concomitant methotrexate. Arthritis Rheum 2010;62(Suppl 10):469
53. Wang J, Kaul S, Campanha H, et al. Multiple ascending dose study of a potent p38 MAPK inhibitor BMS-582949 in subjects with stable RA receiving concomitant methotrexate. ACR/ARHP Scientific Meeting 2008. https://acr.confex. com/acr/2008/ webprogram/Paper4030.html (accessed 1 Sep 2012)
54. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:325-34 (Pubitemid 43343889)
55. Alten R, Zerbini C, Jeka S, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 2010;69:364-7
56. Genovese M, Cohen S, Wofsy D, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 2011;38:846-54
57. Damjanov N, Kauffman RS, Spencer-Green G. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-41
58. Allaart R, Van Haarst A, Martin-Munley S, et al. Two pilot studies of VX-745, an oral p38 mitogen activated protein kinase (MAPK) inhibitor, in patients with rheumatoid arthritis (RA). European League Against Rheumatism. http://www. abstracts2view.com/eular/view.php?nu=EULAR2L1-2002FRI0046&terms= (accessed 1 Sep 2012)
59. Weisman M, Furst D, Shicff M, et al. A double-blind, placebo-controlled trial of VX-745, an oral p38 mitogen activated protein kinase (MAPK) inhibitor, in patients with rheumatoid arthritis (RA). European League Against Rheumatism http://www.abstracts2view.com/eular/view.php?nu=EULAR2L1-2002FRI0018&terms= (accessed 1 Sep 2012)
60. Greenwald MW, Fidelus-Gort R, Levy R, et al. A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active Rheumatoid Arthritis. Arthritis Rheum 2010;62(Suppl 10):2172
61. Boy M, Wang C, Wilkinson B, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009;129:2299-302
62. Burmester G, Blanco R, Charles-Schoeman C, et al. Tofacitinib (cp-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: A 6-month phase 3 study. Arthritis Rheum 2011;63(Supp 10):279
63. Cohen S, Zwillich S, Chow V, et al. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol 2010;69:143-51
64. Kremer J, Li Z, Hall S, et al. Tofacitinib (cp-690,550), an oral Jak inhibitor, in combination with traditional DMARDS : phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDS. Ann Rheum Dis 2011;70(Suppl3):170
65. Takeuchi T, Tanaka Y, Yamanaka H, et al. Tofacitinib (cp-690,550), an oral Janus kinase inhibitor, as monotherapy in patients with active rheumatoid arthritis: A comparison between Japanese and global populations over 12 weeks of dosing in phase 2b studies. Arthrits Rheum 2011;63(Supp 10):472
66. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: A 24-Month Phase 3 Study. Arhtritis Rheum 2011;63(Supp 10):1017
67. Sandborn W, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 16 2012;367:616-24
68. Papp K, Menter A, Tan H, et al. Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, consistently improves the clinical signs of moderate to severe psoriasis in different body regions. J Am Acad Dermatol 2011;64(2 suppl 1): AB153
69. Fleischmann R, Spencer-Green G, Fan F, et al. Dose Ranging Study of VX-509, An Oral Selective JAK3 Inhibitor, As Monotherapy in Patients with Active Rheumatoid Arthritis (RA). Late break abstract session. Late Breaking Abstracts. ACR/ARHP Scientific Meeting. 2011. https://acr.confex.com/acr/2011/ webprogram/Paper24549. html (accessed Sep 2012)
70. Daniels C, Lasky J, Limper A, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181:604-10
71. Ghofrani H, Morrell N, Hoeper M, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-7
72. Khanna D, Saggar R, Mayes MD, et al. Open-label pilot trial of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis- associated active interstitial lung disease (SSc-ILD). Arthritis Rheum 2011;63:3540-6
73. Spiera R, Gordon J, Mersten J, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011;70:1003-9
74. Humbert M, de Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009;64:1194-201
75. Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: A randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 2011;3:16
76. Tebib J, Mariette X, Bourgeois P, et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 2009;11:R95
77. Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: A randomized pilot study. BMC Neurol 2012;12:36
78. Genovese M, Kavanaugh A, Weinblatt M, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63:337-45
79. Podolanczuk A, Lazarus A, Crow A, et al. Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113:3154-60
80. Weinblatt M, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18
81. Weinblatt M, Kavanaugh A, Genovese M, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12.